---
title: "Creative Medical Tech (CELZ.US) — 财务报表"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/CELZ.US/norm.md"
symbol: "CELZ.US"
name: "Creative Medical Tech"
parent: "https://longbridge.com/zh-CN/quote/CELZ.US.md"
datetime: "2026-03-10T01:50:34.594Z"
locales:
  - [en](https://longbridge.com/en/quote/CELZ.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CELZ.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CELZ.US/norm.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/CELZ.US/norm.md) | [繁體中文](https://longbridge.com/zh-HK/quote/CELZ.US/norm.md)


# Creative Medical Tech (CELZ.US) — 财务报表

## 利润表 (USD)

| 指标 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| 每股收益 | -0.4789 | -0.4779 | -0.8270 | -1.09 | -0.7471 |
| ROE | -79.61% | -66.27% | -90.99% | -115.00% | -58.72% |
| 营业收入 | - | - | 3000.00 | 3000.00 | - |
| 净利润 | -1.24M | -1.23M | -1.64M | -1.85M | -1.04M |
| 营业利润 | -1.27M | -1.26M | -1.66M | -1.89M | -1.11M |
| 毛利率 | - | - | 60.00% | 60.00% | - |
| 净利率 | - | - | -54603.23% | -61802.47% | - |
| 利润含金量 | - | - | - | - | - |

## 资产负债表 (USD)

| 指标 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| 资产与负债 | 5.85M | 7.11M | 8.35M | 6.67M | 6.89M |
| 权益乘数 | 1.05 | 1.04 | 1.04 | 1.05 | 1.05 |
| 每股净资产 | 2.17 | 2.65 | 3.12 | 3.63 | 4.93 |
| 资产周转率 | 0.0009 | 0.0008 | 0.0016 | 0.0013 | 0.0011 |
| 现金及短投 | 5.38M | 6.54M | 7.70M | 5.94M | 6.26M |
| 存货与应收 | 994.00 | 994.00 | 994.00 | 2194.00 | 3394.00 |
| 长期投资 | - | - | - | - | - |
| 净债务 | -5.36M | -6.53M | -7.69M | -5.93M | -6.25M |

## 现金流量表 (USD)

| 指标 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| --- | --- | --- | --- | --- | --- |
| 经营现金流 | -1.17M | -1.16M | -1.59M | -1.95M | -985588.00 |
| 投资现金流 | - | - | - | 0.0000 | -200000.00 |
| 融资现金流 | 0.0000 | 0.0000 | 3.35M | 1.63M | -25450.00 |
| 自由现金流 | -728321.00 | -715144.00 | -991237.00 | -1.27M | -848161.00 |
| 现金流充裕率 | - | - | - | - | - |
| 举债与偿债 | - | - | - | - | - |
| 资本支出 | - | - | - | - | - |